Inventor · disambiguated record
Hugh Griffith
Also filed as: GRIFFITH HUGH · GRIFFITH HUGH MCARTHUR
20 granted patents·21 pending applications·61 citations·filing 2003–2025
93Inventor score
Top patents by PatentIndex Score
41 records- 0195US11040051B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2020·Granted Jun 22, 2021·4 cites·20 claims
- 0295US10117888B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2015·Granted Nov 6, 2018·23 cites·29 claims
- 0394US10786523B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2018·Granted Sep 29, 2020·8 cites·24 claims
- 0488US11352387B22′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compoundsNuCana plc·Filed 2020·Granted Jun 7, 2022·2 cites·19 claims
- 0588US10570168B22′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compoundsNuCana plc·Filed 2015·Granted Feb 25, 2020·5 cites·4 claims
- 0685US12357652B2Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2023·Granted Jul 15, 2025·0 cites·20 claims
- 0785US10660912B2Combination therapy for cancerNuCana plc·Filed 2015·Granted May 26, 2020·4 cites·15 claims
- 0884US2025171487A1Synthesis of phosphate derivativesNuCana plc·Filed 2024·Application pending·0 cites
- 0982US10906929B2Phosphoramidate nucleoside derivatives as anticancer agentsNuCana plc·Filed 2017·Granted Feb 2, 2021·2 cites·16 claims
- 1081US10669300B2Methods of separating gemcitabine-phosphate diastereoisomersNuCana plc·Filed 2015·Granted Jun 2, 2020·2 cites·20 claims
- 1180US11414452B2Synthesis of phosphate derivativesNuCana plc·Filed 2018·Granted Aug 16, 2022·1 cites·7 claims
- 1280US10662213B2Gemcitabine prodrugsNuCana plc·Filed 2015·Granted May 26, 2020·3 cites·13 claims
- 1380US2025302859A1Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2025·Application pending·0 cites
- 1479US12054511B2Synthesis of phosphate derivativesNuCana plc·Filed 2022·Granted Aug 6, 2024·0 cites·26 claims
- 1578US2024293439A1Treatment regimensNuCana plc·Filed 2023·Application pending·0 cites
- 1676US2023226092A1Cancer treatments based on gemcitabine prodrugsNuCana plc·Filed 2022·Application pending·0 cites
- 1775US12054510B22′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compoundsNuCana plc·Filed 2022·Granted Aug 6, 2024·0 cites·8 claims
- 1875US11707477B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2021·Granted Jul 25, 2023·0 cites·11 claims
- 1974US11786544B2Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2021·Granted Oct 17, 2023·0 cites·9 claims
- 2073US2022323475A1Combination therapy for cancerNuCana plc·Filed 2022·Application pending·0 cites
- 2171US2023192750A1Salts of diphosphate phosphoramidate of nucleosides as anticancer compoundsNuCana plc·Filed 2022·Application pending·0 cites
- 2270US11400107B2Cancer treatmentsNuCana plc·Filed 2017·Granted Aug 2, 2022·1 cites·16 claims
- 2369US2023149436A1Combination therapyNuCana plc·Filed 2022·Application pending·0 cites
- 2465US2023218655A1Cancer treatmentsNuCana plc·Filed 2022·Application pending·0 cites
- 2564US2021100825A1Cancer treatments based on gemcitabine prodrugsNuCana plc·Filed 2020·Application pending·0 cites
- 2664US2020268783A1Combination therapy for cancerNuCana plc·Filed 2020·Application pending·0 cites
- 2763US2025163096A12' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compoundsNuCana plc·Filed 2024·Application pending·0 cites
- 2863US2021130387A1Phosphoramidate nucleoside derivatives as anticancer agentsNuCana plc·Filed 2021·Application pending·0 cites
- 2962US11629164B2Gemcitabine prodrugsNuCana plc·Filed 2020·Granted Apr 18, 2023·0 cites·10 claims
- 3062US2020345755A1Treatment RegimensNuCana plc·Filed 2018·Application pending·0 cites
- 3155US2019022117A1Combination therapyNuCana plc·Filed 2016·Application pending·0 cites
- 3255US2018289733A1Cancer treatments based on gemcitabine prodrugsNuCana plc·Filed 2015·Application pending·0 cites
- 3355US2022024963A1Salt of triphosphate phosphoramidates of nucleotides as anticancer compoundsNuCana plc·Filed 2021·Application pending·0 cites
- 3455US2018369266A1Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2016·Application pending·0 cites
- 3552US11377467B2Crystalline form of gemcitabineNuCana plc·Filed 2016·Granted Jul 5, 2022·0 cites·5 claims
- 3651US11560400B2Salts of diphosphate phosphoramidate of nucleosides as anticancer compoundsNuCana plc·Filed 2018·Granted Jan 24, 2023·0 cites·27 claims
- 3749US2020197430A1Combination TherapyNuCana plc·Filed 2018·Application pending·0 cites
- 3846USD486850STSP portable electronic toll readerFiled 2003·Granted Feb 17, 2004·6 cites·1 claims
- 3941US2012154372A1Timed reading experience electronic bookBUCK BRIAN·Filed 2011·Application pending·0 cites
- 4040US2019375778A1Adenosine derivatives for use in the treatment of cancerNuCana plc·Filed 2017·Application pending·0 cites
- 4136US2019381084A1Combination therapyNUCANA BIOMED LTD·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hugh Griffith files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →